HARMONI-GI1

1. 12:40
   中文产业新闻精选

   依沃西单抗 HARMONi-GI1 胆道癌头对头试验取得14.9个月总生存期

   依沃西单抗在胆道癌 HARMONi-GI1 III期头对头研究中取得14.9个月总生存期，OS结果显著阳性。该研究是全球首个在胆道癌领域以PD-L1单抗联合化疗为对照、取得OS显著阳性结果的III期研究；TOPAZ-1研究此前确立了度伐利尤单抗联合吉西他滨+顺铂的一线标准治疗地位。

2. 11:58
   中文产业新闻精选

   PD-1/VEGF双抗依沃西联合化疗在HARMONi-GI1三期胆道癌试验中达到OS主要终点

   在2026 ESMO大会公布的HARMONi-GI1三期数据显示，依沃西联合化疗用于一线治疗晚期胆道癌达到OS主要终点。

3. 07:42
   ESMO 2026 现场信号

   “In the control arm, 7% of patients received “Traditional Chinese Medicine” as subsequent antitumor therapy, compared with only 0.6% in the ivonescimab arm.” — @dr_yakupergun on HA
4. 05:13
   ESMO 2026 现场信号

   🚨 Ivonescimab beats durvalumab in biliary tract cancer!
5. 04:47
   ESMO 2026 现场信号

   🔎 HARMONi-GI1 | Safety
6. 03:34
   ESMO 2026 现场信号

   HARMONi-GI1: ivonescimab + chemo vs durvalumab + chemo in first-line advanced #BTC
7. 03:19
   ESMO 2026 现场信号

   ✨@myESMO Presidential Symposium Spotlight✨: Head-to-head vs durvalumab + chemo, ivonescimab + gemcitabine/cisplatin improved OS (HR, 0.75), PFS (HR, 0.61), and ORR in first-line ad
8. 03:17
   ESMO 2026 现场信号

   ✨ @myESMO #ESMO26 Presidential Symposium Spotlight✨: Head-to-head vs durvalumab + chemo, ivonescimab + gemcitabine/cisplatin improved OS (HR, 0.75), PFS (HR, 0.61), and ORR in firs
9. 03:16
   ESMO 2026 现场信号

   HARMONi-GI1: ivonescimab + gem/cis vs durvalumab + gem/cis, 1L biliary tract cancer (China, n=682).
10. 03:02
    ESMO 2026 现场信号

    Can a PD-1/VEGF bispecific raise the bar in advanced biliary tract cancer?
11. 01:48
    ESMO 2026 现场信号

    #ScienceLink #Madrid2026 #ESMO26 #HARMONiGI1 #Ivonescimab
12. 01:12
    ESMO 2026 现场信号

    HARMONi-GI1: OS 14.9 vs 12.1 months.
13. 01:07
    ESMO 2026 现场信号

    HARMONi-GI1 phase 3 trial of ivonescimab + chemo in 1L advanced #BTC
14. 01:05
    ESMO 2026 现场信号

    HARMONI-GI1 at the @myESMO #ESMO26 #Presidential of CisGem + #ivonescimab vs durvalumab in #firstline #BiliaryMalignancies
15. 01:03
    ESMO 2026 现场信号

    🚨 #ESMO26 Plenary | HARMONi-GI1
16. 01:03
    ESMO 2026 现场信号

    🚨 #ESMO26 Presidential Symposium II | HARMONi-GI1 Phase-3 trial
17. 01:02
    ESMO 2026 现场信号

    🔥HARMONi-GI1 ph3 advanced #BTC
18. 01:02
    ESMO 2026 现场信号

    📣 Second Presidential Symposium
19. 01:01
    ESMO 2026 现场信号

    #ESMO26 | HARMONi-GI1
20. 01:01
    ESMO 2026 现场信号

    #ESMO26 🚀 HARMONi-GI1 | Phase III
21. 01:00
    ESMO 2026 现场信号

    The PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy significantly improved overall survival in #BiliaryTractCancer in the phase III HARMONi-GI1 #ClinicalTrial presented
22. 00:57
    ESMO 2026 现场信号

    🔥Presidential session at ESMO 2026 🔥
23. 00:08
    ESMO 2026 现场信号

    $SMMT Ivonescimab Plus Chemotherapy Demonstrates OS Superiority Compared to Durvalumab Plus Chemo in Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study. #ESMO26

1. 22:37
   ESMO 2026 现场信号

   🚨 #ESMO26 Presidential 2 | HARMONi-GI1 Ph3
2. 21:36
   ESMO 2026 现场信号

   🚨 #ESMO26: Durvalumab’s first-line dominance in biliary tract cancer challenged!
3. 18:19
   ESMO 2026 现场信号

   HARMONi-GI1, presidential session at #ESMO26.
4. 18:07
   ESMO 2026 现场信号

   HARMONi-GI1: A meaningful OS gain.
5. 16:37
   ESMO 2026 现场信号

   $SMMT ivonescimab + chemo in Harmoni-GI1, Chinese trial in 1L cholangio. mOS 14.9 vs 12.1 for Imfinzi + chemo (HR=0.75, p=0.0031). Full data later today at #Esmo26 presidential.
6. 16:01
   ESMO 2026 现场信号

   🔥 #ESMO2026 Day 3/25 Oct: Late-breakers scored 1–10 for SoC impact
7. 12:25
   ESMO 2026 现场信号

   🚀Presidential #ESMO26
8. 10:52
   ESMO 2026 现场信号

   #ESMO26 | HARMONi-GI1| Presidential Session-2

当前热度 177·可比范围峰值 195（10月26日 06:00）·近 24 小时可比范围变化 +1804%·当前参与者 26

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。